Clinical trials
Advanced HR+/HER2- Breast Cancer clinical trials
Below are recruiting advanced hr+/her2- breast cancer clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04263298RecruitingPhase 3
Fulvestrant or capecitabine after chemo for metastatic breast cancer
This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.
Guangzhou, GuangdongAges 18–75 - NCT05890287Recruiting
Chidamide plus hormone therapy after chemotherapy for breast cancer
This trial studies chidamide added to standard hormone (endocrine) therapy to help prevent breast cancer from coming back after initial chemotherapy. It may help by keeping cancer under control for longer in people with HR-positive, HER2-negative breast cancer who respond to first-line treatment.
TianjinAges 18–75 - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT05949541RecruitingPhase 2
Everolimus with first-line hormone therapy for specific breast cancer
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06149130RecruitingPhase 2
Testing adebrelimab, dalpiciclib, and hormone therapy for advanced breast cancer
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Wuhan, HubeiAges 18–75 - NCT07810088RecruitingPhase 2
Dalpiciclib with hormone therapy and blood pressure drug for advanced breast cancer
This trial is testing a new combination of medicines — a CDK4/6 inhibitor (dalpiciclib) plus hormone therapy and a blood pressure drug (olmesartan) — as a first treatment for advanced hormone-positive breast cancer. The goal is to see if this combination helps slow or shrink the cancer better than standard care.
Wuhan, HubeiAges 18–75 - NCT07801508RecruitingPhase 1
Trial of a new imaging agent for people with advanced solid tumors
This trial tests a radioactive imaging agent that may help doctors see tumors more clearly using a special scan. It is designed for adults with certain breast, lung, or stomach cancers that have spread.
Darlinghurst, New South WalesAges 18 years+ - NCT06236269RecruitingPhase 2
Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Badalona, BarcelonaAges 18 years+ - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07604571RecruitingPhase 1
Testing IEV407 for Advanced Hormone-Sensitive Breast Cancer
This study tests a new drug called IEV407, either alone or combined with existing hormone therapies, in people with advanced breast cancer that is hormone-receptor positive and HER2 negative. The trial aims to find the right dose and see if this combination helps people whose cancer has stopped responding to previous treatments.
New Haven, ConnecticutAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07531693Recruiting
Improving Outcomes in Early Hormone-Positive Breast Cancer
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
Erlangen, BavariaAges 18 years+ - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT07492641RecruitingPhase 3
A new drug plus letrozole for advanced HR+ breast cancer
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT07476170Recruiting
HR+/HER2- advanced breast cancer treatment patterns in China
This study looks at the real-world treatment patterns and outcomes for people with HR+/HER2- advanced breast cancer who started their first treatment in China between 2024 and 2027. It aims to understand what treatments are used and how well they work in everyday practice.
Bingjie, Beijing MunicipalityAges 18–99 - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT07395336RecruitingPhase 2
Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Milan, ItalyAges 18 years+ - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Advanced HR+/HER2- Breast Cancer trials by city
Studies with a site in or near these metro areas.
Advanced HR+/HER2- Breast Cancer trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for advanced hr+/her2- breast cancer?
- Yes. Clin2 currently lists 71 recruiting advanced hr+/her2- breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced hr+/her2- breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced hr+/her2- breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.